402 related articles for article (PubMed ID: 25387507)
21. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus.
Büsing V; Kern JS; Bruckner-Tuderman L; Hofmann SC
Dermatology; 2010; 221(2):122-6. PubMed ID: 20587990
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of severe refractory pemphigus vulgaris with rituximab].
Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM
Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052
[TBL] [Abstract][Full Text] [Related]
23. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Luger TA
Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
[TBL] [Abstract][Full Text] [Related]
24. Mycophenolate is effective in the treatment of pemphigus vulgaris.
Enk AH; Knop J
Arch Dermatol; 1999 Jan; 135(1):54-6. PubMed ID: 9923781
[TBL] [Abstract][Full Text] [Related]
25. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.
Chams-Davatchi C; Esmaili N; Daneshpazhooh M; Valikhani M; Balighi K; Hallaji Z; Barzegari M; Akhyani M; Ghodsi SZ; Seirafi H; Nazemi MJ; Mortazavi H; Mirshams-Shahshahani M
J Am Acad Dermatol; 2007 Oct; 57(4):622-8. PubMed ID: 17583373
[TBL] [Abstract][Full Text] [Related]
26. [Rituximab induced remission of pemphigus vulgaris: 2 cases].
Borel C; Launay F; Garrouste C; Astudillo L; Bazex J; Arlet P; Paul C; Viraben R; Sailler L
Rev Med Interne; 2007 Apr; 28(4):266-8. PubMed ID: 17188405
[TBL] [Abstract][Full Text] [Related]
27. [Pemphigus: current and future treatment strategies].
Kussini J; Kaisers T; Sequeira Santos AM; Eming R; Didona D
Dermatologie (Heidelb); 2022 Dec; 74(12):915-926. PubMed ID: 37902884
[TBL] [Abstract][Full Text] [Related]
28. Rituximab followed by mycophenolate mofetil in children with IgM nephropathy.
Gu J; Xia Y; Mao J; Fu H; Liu A
Indian Pediatr; 2012 Oct; 49(10):831-3. PubMed ID: 23144102
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris.
Baskan EB; Yilmaz M; Tunali S; Saricaoglu H
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052
[TBL] [Abstract][Full Text] [Related]
30. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations.
Craythorne E; du Viver A; Mufti GJ; Warnakulasuriya S
J Oral Pathol Med; 2011 Sep; 40(8):616-20. PubMed ID: 21385212
[TBL] [Abstract][Full Text] [Related]
31. Seeking approval: present and future therapies for pemphigus vulgaris.
Mao X; Payne AS
Curr Opin Investig Drugs; 2008 May; 9(5):497-504. PubMed ID: 18465660
[TBL] [Abstract][Full Text] [Related]
32. Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris.
Chen MKY; Vissapragada R; Bulamu N; Gupta M; Werth V; Sebaratnam DF
JAMA Dermatol; 2022 Sep; 158(9):1013-1021. PubMed ID: 35895045
[TBL] [Abstract][Full Text] [Related]
33. Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome).
Frew JW; Murrell DF
Dermatol Clin; 2011 Oct; 29(4):607-12. PubMed ID: 21925005
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies.
Schiavo AL; Puca RV; Ruocco V; Ruocco E
Clin Dermatol; 2010; 28(3):337-43. PubMed ID: 20541689
[TBL] [Abstract][Full Text] [Related]
35. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
[TBL] [Abstract][Full Text] [Related]
36. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus.
Cho YT; Lee FY; Chu CY; Wang LF
Acta Derm Venereol; 2014 Jul; 94(4):472-3. PubMed ID: 24217821
[No Abstract] [Full Text] [Related]
37. An evaluation of the usefulness of mycophenolate mofetil in pemphigus.
Powell AM; Albert S; Al Fares S; Harman KE; Setterfield J; Bhogal B; Black MM
Br J Dermatol; 2003 Jul; 149(1):138-45. PubMed ID: 12890207
[TBL] [Abstract][Full Text] [Related]
38. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy.
Yang T; Nast CC; Vo A; Jordan SC
Nephrol Dial Transplant; 2008 Jan; 23(1):377-80. PubMed ID: 17981884
[No Abstract] [Full Text] [Related]
39. Mycophenolate mofetil monotherapy for pemphigus vulgaris.
Bredlich RO; Grundmann-Kollmann M; Behrens S; Kerscher M; Peter RU
Br J Dermatol; 1999 Nov; 141(5):934. PubMed ID: 10583186
[No Abstract] [Full Text] [Related]
40. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
